| Sun Bing,Chang Joe Y.Practice and progress of stereotactic ablative radiotherapy in MD Anderson Cancer Center[J].Chinese Journal of Radiological Medicine and Protection,2016,36(10):721-727 |
| Practice and progress of stereotactic ablative radiotherapy in MD Anderson Cancer Center |
| Received:July 04, 2016 |
| DOI：10.3760/cma.j.issn.0254-5098.2016.10.001 |
| KeyWords:Stereotactic body radiotherapy (SBRT) Stereotactic ablative radiotherapy (SABR) Non-small-cell lung cancer (NSCLC) MD Anderson Cancer Center |
| FundProject: |
|
| Hits: 2837 |
| Download times: 2293 |
| Abstract:: |
| Image-guided stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy) is a non-invasive treatment by delivering ablative doses of radiation over one to ten fractions to tumors, and it achieves local control in excess of 90%. SABR has become a standard treatment for medically inoperable and an option for operable clinical early-stage non-small-cell lung cancer (NSCLC). The university of Texas MD Anderson Cancer Center (MDACC), as a top institute of cancer research and treatment worldwide, has conducted a series of influential SABR clinical trials and researches. The results have greatly promoted the application of SABR in early- and advanced-stage NSCLC. Here we summarize the clinical application, study progresses and findings of SABR for NSCLC in MDACC. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
